Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy

被引:2
|
作者
Halfdanarson, Thorvardur R. [1 ]
Mallak, Nadine [2 ]
Paulson, Scott [3 ]
Chandrasekharan, Chandrikha [4 ]
Natwa, Mona [5 ]
Kendi, Ayse Tuba [1 ]
Kennecke, Hagen F. [6 ]
机构
[1] Mayo Clin, Rochester, MN 55905 USA
[2] Oregon Hlth & Sci Univ, Div Mol Imaging & Therapy, Portland, OR 97239 USA
[3] Texas Oncol, Dallas, TX 75230 USA
[4] Univ Iowa Carver, Coll Med, Iowa City, IA 52242 USA
[5] NYU, Langone Hlth, New York, NY 10016 USA
[6] Providence Canc Inst Franz Clin, Portland, OR 97213 USA
关键词
radioligand therapy; peptide receptor radionuclide therapy; neuroendocrine tumor; response; monitoring; surveillance; positron emission tomography; PET; imaging; somatostatin receptor; RECEPTOR RADIONUCLIDE THERAPY; SOCIETY CONSENSUS GUIDELINES; GA-68-DOTATATE PET/CT; MEDICAL-MANAGEMENT; LU-177-DOTATATE; SURVIVAL; PRRT; HEPATOTOXICITY; Y-90-DOTATOC; PREDICTION;
D O I
10.3390/cancers15194836
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Radioligand therapy with [177Lu]Lu-DOTA-TATE is a therapeutic option for adult patients with somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Patients undergoing radioligand therapy require diligent monitoring and surveillance. While published guidelines can provide guidance on general approaches to care, GEP-NETs are heterogeneous and the guidelines can be difficult to apply in individual and complex cases. In this article, we discuss emerging evidence on imaging, clinical biochemistry, and tumor assessment criteria in the management of patients receiving radioligand therapy for GEP-NETs as well as our own best practices. We offer practical guidance on how to effectively implement monitoring and surveillance measures to aid patient-tailored clinical decision-making.Abstract Radioligand therapy (RLT) with [177Lu]Lu-DOTA-TATE is a standard of care for adult patients with somatostatin-receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Taking advantage of this precision nuclear medicine approach requires diligent monitoring and surveillance, from the use of diagnostic SSTR-targeted radioligand imaging for the selection of patients through treatment and assessments of response. Published evidence-based guidelines assist the multidisciplinary healthcare team by providing acceptable approaches to care; however, the sheer heterogeneity of GEP-NETs can make these frameworks difficult to apply in individual clinical circumstances. There are also contradictions in the literature regarding the utility of novel approaches in monitoring and surveilling patients with GEP-NETs receiving RLT. This article discusses the emerging evidence on imaging, clinical biochemistry, and tumor assessment criteria in the management of patients receiving RLT for GEP-NETs; additionally, it documents our own best practices. This allows us to offer practical guidance on how to effectively implement monitoring and surveillance measures to aid patient-tailored clinical decision-making.
引用
收藏
页数:20
相关论文
共 50 条
  • [31] The management of neuroendocrine gastroenteropancreatic tumors
    Berrad, S.
    Erraichi, H.
    Nouikh, L.
    Messoudi, K.
    Oualla, K.
    Benbrahim, Z.
    Arifi, S.
    Mellas, N.
    ANNALS OF ONCOLOGY, 2019, 30
  • [32] Neuroendocrine gastroenteropancreatic tumors are they hereditary?
    Scherubl, H
    Bredeek, U
    Janson, ET
    Riecken, EO
    Wiedenmann, B
    Skogseid, B
    Quabbe, HJ
    Oberg, K
    GASTROENTEROLOGY, 1997, 112 (04) : A651 - A651
  • [33] Imaging of gastroenteropancreatic neuroendocrine tumors
    Tan, Eik Hock
    Tan, Cher Heng
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2011, 2 (01): : 28 - 43
  • [34] Workup of Gastroenteropancreatic Neuroendocrine Tumors
    Dillon, Joseph S.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2020, 29 (02) : 165 - +
  • [35] Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors
    van Essen, Martijn
    Krenning, Eric P.
    Kam, Boen L. R.
    de Herder, Wouter W.
    Feelders, Richard A.
    Kwekkeboom, Dik J.
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (03) : 383 - 390
  • [36] An Update on Gastroenteropancreatic Neuroendocrine Tumors
    Cives, Mauro
    Strosberg, Jonathan
    ONCOLOGY-NEW YORK, 2014, 28 (09): : 749 - 758
  • [37] RADIOTHERAPY FOR GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS
    KIMMIG, BN
    MOLECULAR AND CELL BIOLOGICAL ASPECTS OF GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR DISEASE, 1994, 733 : 488 - 495
  • [38] Nutrition and Gastroenteropancreatic Neuroendocrine Tumors
    Go, Vay Liang W.
    Srihari, Priya
    Burns, Leigh Anne Kamerman
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2010, 39 (04) : 827 - +
  • [39] Treatment of gastroenteropancreatic neuroendocrine tumors
    U. Plöckinger
    B. Wiedenmann
    Virchows Archiv, 2007, 451 : 71 - 80
  • [40] The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors
    Lawrence, Ben
    Gustafsson, Bjorn I.
    Chan, Anthony
    Svejda, Bernhard
    Kidd, Mark
    Modlin, Irvin M.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2011, 40 (01) : 1 - +